Update on the use of biologics in primary systemic vasculatides

Expert Review of Clinical Immunology

Volumn 3, Issue 6, 2007, Pages 901-911

  Mukhtyar, Chetan ^a   Chan, Antoni ^b   Luqmani, Raashid ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

Anti TNF therapy; Biologic therapy; Intravenous immunoglobulin; Rituximab; Vasculitis

Indexed keywords

15 DEOXYSPERGUALIN; ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYTOKINE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PLACEBO; PREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AORTA ARCH SYNDROME; ASTHMA; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; BLADDER CANCER; CHURG STRAUSS SYNDROME; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; FOLLOW UP; GIANT CELL ARTERITIS; GLOMERULONEPHRITIS; HEMORRHAGIC CYSTITIS; HEPATITIS C; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUROLOGIC DISEASE; PLASMAPHERESIS; POLYARTERITIS NODOSA; PREDICTION; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SOLID TUMOR; STANDARDIZATION; SYSTEMIC VASCULITIS; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT TUMOR; VISUAL IMPAIRMENT; WEGENER GRANULOMATOSIS;

EID: 36248976627     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.6.901     Document Type: Review

References (118)

1. Fries JF, Hunder GG, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 33(8), 1135-1136 (1990).
2. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37(2), 187-192 (1994).
3. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann. Intern. Med. 129(5), 345-352 (1998).
4. Guillevin L, Cordier JF, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 40(12), 2187-2198 (1997).
5. Haubitz M, Schellong S, Gobel U et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 41(10), 1835-1844 (1998).
6. De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52(8), 2461-2469 (2005).
7. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349(1), 36-44 (2003).
8. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 347(4), 261-271 (2002).
9. Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J. Clin. Pathol. 55(7), 481-486 (2002).
10. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum. 42(12), 2507-2516 (1999).
11. Knobler RL, Panitch HS, Braheny SL et al. Systemic α-interferon therapy of multiple sclerosis. Neurology 34(10), 1273-1279 (1984).
12. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343(22), 1594-1602 (2000).
13. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum. 53(1), 93-99 (2005).
14. Baldursson O, Steinsson K, Bjornsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum. 37(7), 1007-1012 (1994).
15. Ramstead CL, Patel AD. Giant cell arteritis in a neuro-ophthalmology clinic in Saskatoon, 1998-2003. Can. J. Ophthalmol. 42(2), 295-298 (2007).
16. Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Influence of age, sex, and place of residence on clinical expression of giant cell arteritis in northwest Spain. J. Rheumatol. 30(7), 1548-1551 (2003).
17. Salvarani C, Macchioni PL, Tartoni PL et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin. Exp. Rheumatol. 5(3), 205-215 (1987).
18. Sonnenblick M, Nesher G, Friedlander Y, Rubinow A. Giant cell arteritis in Jerusalem: a 12-year epidemiological study. Br. J. Rheumatol. 33(10), 938-941 (1994).
19. Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum. 43(11), 2481-2487 (2000).
20. Carruthers DM, Watts RA, Symmons DP, Scott DG. Wegener's granulomatosis - increased incidence or increased recognition? Br. J. Rheumatol. 35(2), 142-145 (1996).
21. Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, Rodriguez-Ledo P, Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann. Rheum. Dis. 60(4), 367-371 (2001).
22. Rajala SA, Ahvenainen JE, Mattila KJ, Saarni MI. Incidence and survival rate in cases of biopsy-proven temporal arteritis. Scand. J. Rheumatol. 22(6), 289-291 (1993).
23. Selga D, Mohammad A, Sturfelt G, Segelmark M. Polyarteritis nodosa when applying the Chapel Hill nomenclature - a descriptive study on ten patients. Rheumatology (Oxford) 45(10), 1276-12781 (2006).
24. Hotchi M. Pathological studies on Takayasu arteritis. Heart Vessels (Suppl. 7), 11-17 (1992).
25. Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum. 48(3), 814-823 (2003).
26. Pfister H, Ollert M, Frohlich LF et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104(5), 1411-1418 (2004).
27. Deguchi Y, Shibata N, Kishimoto S. Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin. Exp. Immunol. 81(2), 311-314 (1990).
28. - T cells are a major source of interferon-γ and tumor necrosis factor-α in Wegener's granulomatosis. Am. J. Pathol. 160(5), 1717-1724 (2002).
29. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin. Exp. Immunol. 95(2), 244-250 (1994).
30. Takizawa M, Maguchi S, Nakamaru Y, Miyatake Y, Fukuda S, Inuyama V. Correlation between the levels of circulating adhesion molecules and PR3-ANCA in Wegener's granulomatosis. Auris Nasus Larynx (28 SuppL), S59-S62 (2001).
31. Moosig F, Csernok E, Kumanovics G, Gross WL. Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-α (TNF-α). Clin. Exp. Immunol. 122(3), 499-503 (2000).
32. van Rossum AP, Limburg PC, Kallenberg CG. Activation, apoptosis, and clearance of neutrophils in Wegener's granulomatosis. Ann. NY Acad. Sci. 1051, 1-11 (2005).
33. Calderwood JW, Williams JM, Morgan MD, Nash GB, Savage CO. ANCA induces β2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J. Leukoc. Biol. 77(1), 33-43 (2005).
34. Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener's granulomatosis. N. Engl. J. Med. 284(17), 938-942 (1971).
35. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med. 98(1), 76-85 (1983).
36. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. 16(10), 2018-2027 (2001).
37. Stillwell TJ, Benson RC Jr, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum. 31(4), 465-470 (1988).
38. Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann. Intern. Med. 124(5), 477-484 (1996).
39. Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18(7), 2180-2188 (2007).
40. Guillevin L, Fain O, Lhote F et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum. 35(2), 208-215 (1992).
41. Guillevin L, Lhote F, Cohen P et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 38(11), 1638-1645 (1995).
42. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann. Rheum. Dis. 66(6), 798-802 (2007).
43. Birck R, Warnatz K, Lorenz HM et al. 15-deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol. 14(2), 440-447 (2003).
44. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am. J. Med. 114(6), 463-469 (2003).
45. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 51(2), 269-273 (2004).
46. Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am. J. Kidney Dis. 47(1), 15-23 (2006).
47. Metzler C, Miehle N, Manger K et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46(7), 1087-1091 (2007).
48. Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin. Pract. 102(3-4), c100-c107 (2006).
49. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J. Rheumatol. 30(1), 80-88 (2003).
50. Hogan SL, Falk RJ, Chin H et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143(9), 621-631 (2005).
51. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 40(2), 371-380 (1997).
52. Guillevin L, Cohen P, Mahr A et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 49(1), 93-100 (2003).
53. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78(1), 26-37 (1999).
54. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 66(5), 605-617 (2007).
55. Mukhtyar C, Hellmich B, Jayne D, Flossmann O, Luqmani R. Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clin. Exp. Rheumatol. 24(6 Suppl. 43), S93-S98 (2006).
56. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352(4), 351-361 (2005).
57. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 44(5), 1149-1154 (2001).
58. Stone JH, Holbrook JT, Marriott MA et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 54(5), 1608-1618 (2006).
59. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNFα blockade in relapsing vasculitis. Ann. Rheum. Dis. 61(6), 559 (2002).
60. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41(10), 1126-1132 (2002).
61. Booth A, Harper L, Hammad T et al. Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 15(3), 717-721 (2004).
62. Lamprecht P, Voswinkel J, Lilienthal T et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41(11), 1303-1307 (2002).
63. Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {α} blockade in Wegener's granulomatosis. Ann. Rheum. Dis. (64 Suppl. 4), iv31-iv36 (2005).
64. Booth AD, Jayne DR, Kharbanda RK et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109(14), 1718-1723 (2004).
65. Keogh KA, Ytterberg SR, Fervenza PC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173(2), 180-187 (2006).
66. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52(1), 262-268 (2005).
67. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45(11), 1432-1436 (2006).
68. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54(9), 2970-2982 (2006).
69. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 65(4), 1440-1448 (2004).
70. Strasser-Fuchs S, Fazekas F, Deisenhammer F, Nahler G, Mamoli B. The Austrian Immunoglobulin in MS (AIMS) Study: final analysis. Mult. Scler. (6 Suppl. 2), S9-S13 (2000).
71. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. 41(6), 789-796 (1997).
72. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/ Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet 349(9047), 225-230 (1997).
73. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93(7), 433-439 (2000).
74. Muso E, Ito-Ihara T, Ono T et al. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn. J. Infect. Dis. 57(5), S17-S18 (2004).
75. Tatsis E, Schnabel A, Gross WL. Interferon-α treatment of four patients with the Churg-Strauss syndrome. Ann. Intern. Med. 129(5), 370-374 (1998).
76. Metzler C, Lamprecht P, Hellmich B, Reuter M, Arlt AC, Gross WL. Leucoencephalopathy after treatment of Churg-Strauss syndrome with interferon α. Ann. Rheum. Dis. 64(8), 1242-1243 (2005).
77. Guillevin L, Lhote F, Cohen P et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 74(5), 238-253 (1995).
78. Misiani R, Bellavita P, Fenili D et al. Interferon α-2a therapy in cryoglobulinemia associated with hepatitis C virus. N. Engl. J. Med. 330(11), 751-756 (1994).
79. Shiota Y, Matsumoto H, Kanehisa Y et al. Serum interleukin-5 levels in a case with allergic granulomatous angiitis. Intern. Med. 36(10), 709-711 (1997).
80. Kurosawa M, Nakagami R, Morioka J et al. Interleukins in Churg-Strauss syndrome. Allergy 55(8), 785-787 (2000).
81. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann. NY Acad. Sci. 1051, 121-131 (2005).
82. Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA (2002) step 4 treatment): INNOVATE. Allergy 60(3), 309-316 (2005).
83. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J. Allergy Clin. Immunol. 119(5), 1279 (2007).
84. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N. Engl. J. Med. 355(12), 1281-1282 (2006).
85. Casato M, Lagana B, Pucillo LP, Quinti I. Interferon for hepatitis C virus-negative type II mixed cryoglobulinemia. N. Engl. J. Med. 338(19), 1386-1387 (1998).
86. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am. J. Kidney Dis. 43(5), e34-e38 (2004).
87. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann. Rheum. Dis. 61(10), 922-924 (2002).
88. Koukoulaki M, Abeygunasekara SC, Smith KG, Jayne DR. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol. Dial. Transplant. 20(1), 213-216 (2005).
89. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101(10), 3827-3834 (2003).
90. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 101(10), 3818-3826 (2003).
91. Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann. Intern. Med. 82(5), 613-618 (1975).
92. Hoffman GS, Cid MC, Hellmann DB et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 46(5), 1309-1318 (2002).
93. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 49(5), 703-708 (2003).
94. Mahr AD, Jover JA, Spiera RF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56(8), 2789-2797 (2007).
95. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 112(6), 1098-1103 (2005).
96. Foroozan R, Deramno VA, Buono LM et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 110(3), 539-542 (2003).
97. Liozon E, Herrmann F, Ly K et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am. J. Med. 111(3), 211-217 (2001).
98. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 37(4), 578-582 (1994).
99. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J. Rheumatol. 30(8), 1793-1798 (2003).
100. Airo P, Antonioli CM, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 41(3), 347-349 (2002).
101. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 44(12), 2933-2935 (2001).
102. Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J. Rheumatol. 31(7), 1467 (2004).
103. Docken WP. Treatment of resistant giant cell arteritis with etanercept. Ann. Rheum. Dis. 63(4), 469-470 (2004).
104. Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 49(6), 826-837 (2003).
105. Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM. Treatment of refractory temporal arteritis with adalimumab. Clin. Rheumatol. 26(8), 1353-1355 (2006).
106. Hoffman GS, Cid MC, Rendt-Zagar KE et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern. Med. 146(9), 621-630 (2007).
107. Luqmani R. Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward? Ann. Intern. Med. 146(9), 674-676 (2007).
108. Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann. Rheum. Dis. 64(7), 1099-1100 (2005).
109. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 50(7), 2296-2304 (2004).
110. Tato F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int. Angiol. 24(3), 304-307 (2005).
111. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5), 1088-1094 (2001).
112. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337(15), 1029-1035 (1997).
113. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?" Clin. Immunol. 117(3), 207-213 (2005).
114. Tso E, Flamm SD, White RD, Schvartzman PR, Mascha E, Hoffman GS. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum. 46(6), 1634-1642 (2002).
115. Dougados M, Betteridge N, Burmester GR et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann. Rheum. Dis. 63(9), 1172-1176 (2004).
116. Exley AR, Carruthers DM, Luqmani RA et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM 90(6), 391-399 (1997).
117. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 41(5), 572-581 (2002).
118. Lozano E, Segarra M, Garcia-tinez A, Hernandez-Rodriguez J, Cid MC. Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant-cell arteritis. Ann. Rheum. Dis. COI: ard.2007.070805v1 (Epub ahead of print) (2007).